cetpinhibition.org

Torcetrapib

A structural-and-metabolic-network computational model predicts off-target causes of the hypertensive side effect of torcetrapib in kidney tissue (PLoS Comput Biol 2010)

Original title: Drug off-target effects predicted using structural analysis in the context of a metabolic network model

PLoS Comput Biol · · 5

Chang RL, Xie L, Xie L, Bourne PE, Palsson BØ

Combining structural bioinformatics prediction of protein-drug off-targets from ligand binding sites with a large-scale metabolic network model, researchers built a computational framework to evaluate metabolic drug response phenotypes for the hypertensive side effect of torcetrapib, using a metabolic kidney model to simulate drug treatment. The analysis predicted causal off-targets for torcetrapib that had previously been observed to impair renal function in patients deficient in the corresponding genes, potentially explaining the adverse effects seen in torcetrapib clinical trials. The model also predicted genetic risk factors for drug treatment, including both characterized and unknown renal metabolic disorders and cryptic genetic deficiencies not expected to cause a renal phenotype except under drug treatment, representing an early step toward computational systems medicine for predicting drug off-target risk.

Read the paper (DOI)PubMed

Original abstract

Recent advances in structural bioinformatics have enabled the prediction of protein-drug off-targets based on their ligand binding sites. Concurrent developments in systems biology allow for prediction of the functional effects of system perturbations using large-scale network models. Integration of these two capabilities provides a framework for evaluating metabolic drug response phenotypes in silico. This combined approach was applied to investigate the hypertensive side effect of the cholesteryl ester transfer protein inhibitor torcetrapib in the context of human renal function. A metabolic kidney model was generated in which to simulate drug treatment. Causal drug off-targets were predicted that have previously been observed to impact renal function in gene-deficient patients and may play a role in the adverse side effects observed in clinical trials. Genetic risk factors for drug treatment were also predicted that correspond to both characterized and unknown renal metabolic disorders as well as cryptic genetic deficiencies that are not expected to exhibit a renal disorder phenotype except under drug treatment. This study represents a novel integration of structural and systems biology and a first step towards computational systems medicine. The methodology introduced herein has important implications for drug development and personalized medicine.

kidneymechanismstorcetrapib

Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 18 August 2026. Methods.